Tony Ho Email Address

Biotech Entrepreneur

CRISPR Therapeutics is a global organization with three locations in the United States and Europe: Cambridge, MA: Our Cambridge facility is our R&D hub. London, UK: Our London facility is home to European business functions. Basel, Switzerland: Our corporate headquarters are located in Basel. We are always on the look-out for top scientific talent who can help build CRISPR Therapeutics into a world-class gene editing company.

Tony is EVP, Head of R&D at CRISPR Therapeutics. He was previously SVP and Head of Oncology Integration and Innovation at AstraZeneca and oversaw the development and commercialization of Lynparza and Imfinizi (anti-PD-L1). 12 Phase 3 trials designed under his leadership have now read out positive (Lynparza: SOLO1, SOLO2, SOLO3-1L & PSR Ovarian, Olympia, OlympiAD-TNBC, POLO-Pancreatic, PAOLA - 1L Ovarian, ProFound 2L mCRC, ; Imfinzi: Pacific- NSCLC, CASPIAN 1L SCLC, Poseidon 1L NSCLC (IO+IO+CHEMO) Himalaya HCC. Tony has successfully repositioned a failed NK3 antagonist for PCOS and won the 2013 AZ Patent of the Year Award. Tony co-authored two oncology review articles on oncology drug development and the use of intermediate endpoint. Prior to joining AstraZeneca, Tony was the head of Neurology and Ophthalmology at Merck and led several Phase 3 programs including CGRP-RA for migraine, A2a-RA for Parkinson's disease, prostaglandin for glaucoma, and several early programs in neuropathic pain, stroke, Alzheimer’s disease, and alcohol abuse. He has pioneered several novel pain trial designs and has also devised several strategies in decreasing placebo rate. He successfully filed and launched Zioptan four years earlier than initially planned and obtained Maxalt pediatric indication. The FDA praised the pediatric study design in a 2013 review paper. Prior to Merck, Tony was the Co-Founder and CSO of Neuronyx, a start-up that developed stem cells for heart failure, immuno-oncology and islet cells. Tony received B.S. in Electrical Engineering at the UCLA, and M.D. from the Johns Hopkins. He was Assistant Professor at Johns Hopkins specialized in neuropathy and neuromuscular diseases. Tony describing and elucidating the pathogenesis of a new disease called "acute motor axonal neuropathy (AMAN)". He has published widely in several fields with over 80 papers. He is currently Adjunct Associate Professor of Neurology at University of Pennsylvania and Assistant Professor of Neurology at Johns Hopkins University.